전체 프로그램

ADC 890 · Antibody 4071 · CGT 2714 · 다음 갱신 D-5 · 마지막 9월 2일

PopularRecently updatedCuratedMost trialsNeeds refreshORRLatestPhase 3FDA approved153 programs
AntibodyLimited DatastaleAbbViePhase 1

Lemzoparlimab (Lemzoparlimab)

Multiple Myeloma · Multiple Myeloma

#MultipleMyeloma#Antibody#Phase1#monoclonal-antibody#AbbVie
Trials 1Status Discontinued
CGTLimited DatastaleMemorial Sloan Kettering Cancer…Phase 1

MCARH109 (MCARH109)

Multiple Myeloma; Refractory Multiple Myeloma · FRα

#FR#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting
CGTLimited DatastaleMemorial Sloan Kettering Cancer…Phase 1

MCARH125 (MCARH125)

Multiple Myeloma; Refractory Multiple Myeloma · FRα

#FR#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting
AntibodyLimited DatastalePfizerPhase 1

Maplirpacept (Maplirpacept)

Multiple Myeloma · Multiple Myeloma

#MultipleMyeloma#Antibody#Phase1#monoclonal-antibody#Pfizer
Trials 1Status Recruiting
AntibodyLimited DatastalePfizerPhase 1

PF-07901801 (Maplirpacept, Maplirpacept (PF-07901801))

Lymphoma; Multiple Myeloma · Lymphoma

#Lymphoma#Antibody#Phase1#monoclonal-antibody#MultipleMyeloma+1
Trials 1Status Discontinued
CGTLimited DatastaleLeman Biotech Co., Ltd.Phase 1

Metabolically Armed BCMA CAR-T cells. (Metabolically Armed BCMA CAR-T cells.)

Multiple Myeloma (MM); Plasma Cell Leukemia (PCL) · BCMA

#BCMA#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting
CGTLimited DatastaleHadassah Medical OrganizationPhase 1

Naive HBI0101 CAR-T (Naive HBI0101 CAR-T)

Relapsed/Refractory Multiple Myeloma (MM) · FRα

#FR#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting
CGTLimited DatastaleHebei Taihe Chunyu Biotechnolog…Phase 2

Nanobody-based biepitope BCMA-targeting CAR-T cells (Nanobody-based biepitope BCMA-targeting CAR-T cells)

Multiple Myeloma · BCMA

#BCMA#CGT#Phase2#cell-gene-therapy#CAR-T+3
Trials 1Status Recruiting
AntibodyLimited DatastaleZenas BioPharma (USA), LLCPhase 2

Obexelimab (Obexelimab)

Relapsing Multiple Sclerosis · Relapsing Multiple Sclerosis

#RelapsingMultipleSclerosis#Antibody#Phase2#monoclonal-antibody#Zenas
Trials 1Status Recruiting
CGTLimited DatastalePoseida Therapeutics, Inc.Phase 2

P-BCMA-101 CAR-T cells (P-BCMA-101 CAR-T cells)

Multiple Myeloma · BCMA

#BCMA#CGT#Phase2#cell-gene-therapy#CAR-T+3
Trials 1Status Discontinued
CGTLimited DatastalePoseida Therapeutics, Inc.Phase 1

P-BCMA-ALLO1 CAR-T cells (P-BCMA-ALLO1 CAR-T cells)

Multiple Myeloma · BCMA

#BCMA#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 1Status Recruiting
CGTLimited DatastalePrecision BioSciences, Inc.Phase 1

PBCAR269A (PBCAR269A)

Relapsed/Refractory Multiple Myeloma · FRα

#FR#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 1Status Discontinued
CGTLimited DatastaleDaihong LiuPhase 2

PD-1Ab21-BCMA CAR-T cell immunotherapy (PD-1Ab21-BCMA CAR-T cell immunotherapy)

Multiple Myeloma · PD-1

#PD-1#CGT#Phase2#cell-gene-therapy#CAR-T+3
Trials 1Status Recruiting
AntibodyLimited DatastaleRennes University HospitalPhase 3

Perfusion of treatment Ocrelizumab (Perfusion of treatment Ocrelizumab)

Multiple Sclerosis; Relapsing-remitting Multiple Sclerosis · Multiple Sclerosis

#MultipleSclerosis#Antibody#Phase3#monoclonal-antibody#Relapsing-remittingMultipleScler+1
Trials 1Status Recruiting
AntibodyLimited DatastaleRochePhase 3

Perfusion of treatment Rituximab (Perfusion of treatment Rituximab)

Multiple Sclerosis; Relapsing-remitting Multiple Sclerosis · Multiple Sclerosis

#MultipleSclerosis#Antibody#Phase3#monoclonal-antibody#Relapsing-remittingMultipleScler+1
Trials 1Status Recruiting
AntibodyLimited DatastaleJanssenPhase 2

daratumumab (Darzalex, QL2109 or Daratumumab)

Relapsed or Refractory Multiple Myeloma · FRα

#FR#Antibody#Phase2#monoclonal-antibody#RelapsedorRefractoryMultipleMyel+1
Trials 1Status Recruiting
AntibodyLimited DatastaleRegeneron PharmaceuticalsPhase 2

REGN17372+Linvoseltamab (REGN17372+Linvoseltamab)

Relapsed Refractory Multiple Myeloma (RRMM) · FRα

#FR#Antibody#Phase2#monoclonal-antibody#RelapsedRefractoryMultipleMyelom+1
Trials 1Status Recruiting
CGTLimited DatastaleDonghua ZhangPreclinical

Recurrent/refractory multiple myeloma (Recurrent/refractory multiple myeloma, Recurrent/refractory multiple myeloma (r/r MM) patients received infusion of BCMA-GPRC5D CAR-T cells, r/r MM)

Multiple Myeloma · BCMA

#BCMA#CGT#Preclinical#cell-gene-therapy#CAR-T+3
Trials 1Status Recruiting
AntibodyLimited DatastaleSeagen Inc.Phase 2

anti-huCD40 mAb (SGN-40, SGN-40 (anti-huCD40 mAb))

Leukemia, Lymphocytic, Chronic · Multiple Myeloma

#MultipleMyeloma#Antibody#Phase2#monoclonal-antibody#Leukemia+3
Trials 1Status Active
CGTLimited DatastaleWuerzburg University HospitalPhase 2

SLAMF7 CAR-T (SLAMF7 CAR-T)

Multiple Myeloma · Multiple Myeloma

#MultipleMyeloma#CGT#Phase2#cell-gene-therapy#CAR-T+2
Trials 1Status Active

7 / 8 pages

← PreviousNext →